BIOMAT Database Logo BIOMAT Database Logo

Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. 2001

F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
Department of Medicine, Saarland University Medical School D-66421 Homburg, Germany.

The natural killer cell-activating anti-CD16/CD30 bispecific monoclonal antibody (BiMAb) had shown efficacy in a Phase I/II trial of refractory Hodgkin's disease (HD). To gain additional information on clinical efficacy and to investigate the effects of different application schedules and the concomitant application of cytokines, we performed a second randomized pilot trial using this BiMAb in patients with refractory HD. Patients received 4 x 25 mg HRS-3/A9 either as a continuous infusion for 4 days or as a 1-h infusion every other day. In case of an objective response, retreatment was attempted after 4 weeks; in case of stable disease (SD), a second course was given after prestimulation with interleukin 2 and followed by granulocyte macrophage colony-stimulating factor s.c. A total of 16 heavily pretreated patients received one to four BiMAb courses. Overall, we observed one complete remission and three partial remissions lasting 5-9 months (three of four of these responses occurred after continuous BiMAb infusion) and four cases of SD for 3 to >6 months. Interleukin 2 pretreatment before the second BiMAb course resulted in a significant increase of circulating natural killer cells in all five patients treated. This coincided with the conversion of two cases of SD into one complete remission and one partial remission. HRS-3/A9-related side effects consisted of mild fever in only six patients. In summary, this second trial confirmed the antitumor efficacy of this BiMAb against HD and the minor toxicity of this BiMAb. Coadministration of cytokines might contribute to an augmented antitumor activity, and additional clinical trials are warranted to optimize this novel treatment modality.

UI MeSH Term Description Entries
D007260 Infusion Pumps Fluid propulsion systems driven mechanically, electrically, or osmotically that are used to inject (or infuse) over time agents into a patient or experimental animal; used routinely in hospitals to maintain a patent intravenous line, to administer antineoplastic agents and other drugs in thromboembolism, heart disease, diabetes mellitus (INSULIN INFUSION SYSTEMS is also available), and other disorders. Drug Infusion Systems,Infusion Pump,Infusion Pumps, External,Infusors,Intravenous Drug Delivery System,Intravenous Drug Delivery Systems,Perfusion Pumps,Pumps, Infusion,Drug Infusion System,External Infusion Pump,External Infusion Pumps,Infusion Pump, External,Infusion System, Drug,Infusion Systems, Drug,Infusor,Perfusion Pump,Pump, External Infusion,Pump, Infusion,Pump, Perfusion,Pumps, External Infusion,Pumps, Perfusion,System, Drug Infusion,Systems, Drug Infusion
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias

Related Publications

F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
April 2001, Cancer immunology, immunotherapy : CII,
F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
November 1993, International journal of cancer,
F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
[Construction and expression of anti-GD2/anti-CD16 single-chain bispecific antibody].
June 2007, Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi,
F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
September 1998, British journal of haematology,
F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.
July 2021, Clinical cancer research : an official journal of the American Association for Cancer Research,
F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
July 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
January 1997, Cancer immunology, immunotherapy : CII,
F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells.
November 2003, Biochemical and biophysical research communications,
F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
June 1992, British journal of haematology,
F Hartmann, and C Renner, and W Jung, and L da Costa, and S Tembrink, and G Held, and A Sek, and J König, and S Bauer, and M Kloft, and M Pfreundschuh
Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting.
July 2001, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!